Novavax Announces Progress on Sanofi Agreement
Novavax (Nasdaq: NVAX) has expanded its collaboration with Sanofi through an amended license agreement for Novavax's Matrix-M® adjuvant. The amendment allows Sanofi to use Matrix-M in their pandemic influenza vaccine candidate program through Phase 2 development, supported by BARDA funding.
Under the original agreement terms, Novavax can receive up to $200 million for the first four Sanofi products using Matrix-M, and up to $210 million in milestone payments for each subsequent product, plus ongoing royalties. The companies will negotiate additional terms if Sanofi proceeds to Phase 3 development.
Novavax (Nasdaq: NVAX) ha ampliato la sua collaborazione con Sanofi tramite un accordo di licenza modificato per l’adiuvante Matrix-M®. La modifica permette a Sanofi di utilizzare Matrix-M nel programma di vaccino candidato contro l’influenza pandemica fino al livello di sviluppo della fase 2, con finanziamenti BARDA a supporto.
Secondo i termini dell’accordo originale, Novavax può ricevere fino a 200 milioni di dollari per i primi quattro prodotti Sanofi che impiegano Matrix-M e fino a 210 milioni di dollari in pagamenti di traguardo per ogni prodotto successivo, oltre a royalty continue. Le aziende negozieranno ulteriori condizioni se Sanofi procedesse allo sviluppo di fase 3.
Novavax (Nasdaq: NVAX) ha ampliado su colaboración con Sanofi mediante un acuerdo de licencia modificado para el adyuvante Matrix-M®. La enmienda permite a Sanofi usar Matrix-M en su programa de vacuna candidata contra la gripe pandémica hasta el desarrollo en la fase 2, con apoyo de financiación de BARDA.
Según los términos del acuerdo original, Novavax puede recibir hasta 200 millones de dólares por los primeros cuatro productos de Sanofi que utilicen Matrix-M y hasta 210 millones de dólares en pagos por hitos para cada producto posterior, además de regalías continuas. Las compañías negociarán términos adicionales si Sanofi avanza al desarrollo de la fase 3.
Novavax (Nasdaq: NVAX)가 Matrix-M® 보조제에 대한 라이선스 계약을 수정하며 Sanofi와의 협력을 확장했습니다. 개정은 Sanofi가 팬데믹 인플루엔자 백신 후보 프로그램에서 2상 개발까지 Matrix-M을 사용할 수 있도록 허용합니다. BARDA 자금 지원이 포함됩니다.
원래 계약 조건에 따라 Novavax는 Matrix-M을 사용하는 최초의 네 개의 Sanofi 제품에 대해 최대 2억 달러, 이후 각 차기 제품에 대해 최대 2.1천만 달러의 이정(마일스톤) 지급과 지속 로열티를 받을 수 있습니다. Sanofi가 3상 개발로 진행하면 추가 조건을 협상합니다.
Novavax (Nasdaq: NVAX) a étendu sa collaboration avec Sanofi via un amendement de licence pour l’adjuvant Matrix-M®. L’amendement permet à Sanofi d’utiliser Matrix-M dans son programme de vaccin candidat contre la grippe pandémique jusqu’au développement en phase 2, avec un financement BARDA à l’appui.
Selon les termes de l’accord initial, Novavax peut recevoir jusqu’à 200 millions de dollars pour les quatre premiers produits Sanofi utilisant Matrix-M, et jusqu’à 210 millions de dollars de paiements d’étapes pour chaque produit suivant, en plus de redevances continues. Les entreprises négocieront des termes supplémentaires si Sanofi poursuit le développement en phase 3.
Novavax (Nasdaq: NVAX) hat seine Zusammenarbeit mit Sanofi durch eine geänderte Lizenzvereinbarung für den Matrix-M®-Adjuvans erweitert. Die Änderung erlaubt Sanofi, Matrix-M in ihrem Pandemie-Grippe-Impfstoffkandidatenprogramm bis zur Phase 2 zu verwenden, unterstützt durch BARDA-Fördermittel.
Nach den ursprünglichen Vereinbarungsbedingungen kann Novavax bis zu 200 Millionen USD für die ersten vier Sanofi-Produkte, die Matrix-M verwenden, erhalten und bis zu 210 Millionen USD an Meilensteinzahlungen für jedes nachfolgende Produkt sowie fortlaufende Lizenzgebühren. Die Unternehmen werden zusätzliche Bedingungen verhandeln, falls Sanofi in die Phase-3-Entwicklung übergeht.
Novavax (Nasdaq: NVAX) قد وسّعت تعاونها مع Sanofi من خلال تعديل اتفاقية الترخيص لمساعد Matrix-M®. يسمح التعديل لـSanofi باستخدام Matrix-M في برنامج لقاح الإنفلونزا الوبائية حتى التطوير بالمرحلة 2، مدعومًا بتمويل BARDA.
وفقًا لشروط الاتفاق الأصلي، يمكن لـNovavax أن تتلقى حتى مئتي مليون دولار لأربعة منتجات Sanofi الأولى التي تستخدم Matrix-M، وحتى 210 ملايين دولار كمدفوعات معلمية لكل منتج لاحق، بالإضافة إلى الإتاوات المستمرة. ست negotiate الشركات شروطاً إضافية إذا تقدمت Sanofi إلى تطوير المرحلة 3.
Novavax（纳斯达克：NVAX） 通过经修订的 Matrix-M® 佐剂许可协议扩大了与 Sanofi 的合作。修订允许 Sanofi 在其对流感大流行疫苗候选项目中使用 Matrix-M，直至二期开发阶段，并获得 BARDA 的资金支持。
根据原始协议条款，Novavax 对前四个使用 Matrix-M 的 Sanofi 产品最高可获得 2亿美元，对于每个后续产品最高可获得 2.1亿美元 的里程碑款，以及持续的特许权使用费。若 Sanofi 进入三期开发，双方将就额外条款进行协商。
- Expansion of existing partnership with major pharma company Sanofi
- Potential revenue of up to $200 million for first four products
- Additional milestone payments of up to $210 million per subsequent product
- Ongoing royalty payments for all Sanofi products using Matrix-M
- Government backing through BARDA funding support
- Phase 3 financial terms not yet determined
- Early-stage development status indicates long timeline to potential commercialization
Insights
Novavax expands Sanofi partnership for Matrix-M adjuvant in pandemic influenza vaccines, boosting potential revenue streams and market validation.
This amendment to Novavax's collaboration with Sanofi represents a strategic expansion of their partnership, now including the use of Novavax's Matrix-M® adjuvant technology in Sanofi's pandemic influenza vaccine development program. The deal is particularly significant as it comes with
The structured deal intelligently limits initial commitment to early-stage development through Phase 2 trials, with terms for Phase 3 to be negotiated later - a prudent risk management approach for both companies. Financially, this builds upon the original agreement's potential for up to
This partnership extension accomplishes several strategic objectives for Novavax: it diversifies revenue potential beyond COVID-19 vaccines, validates their adjuvant technology through adoption by a major pharmaceutical player, and strengthens their position in pandemic preparedness - a market with sustained government interest and funding. The amendment also suggests Sanofi's satisfaction with initial collaboration results, as they're now "exploring additional opportunities with Matrix-M."
For a company that has faced challenges pivoting beyond its COVID-19 portfolio, this expanded partnership demonstrates that Novavax's platform technology has broader applications and commercial value, potentially helping to stabilize and diversify future revenue streams.
The CLA amendment enables Sanofi's use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate(s) through Phase 2. If Sanofi enters Phase 3 clinical development, the parties will negotiate license rates and financial terms.
"We're excited that Sanofi has recognized the potential of a pandemic influenza vaccine candidate that contains Novavax's validated Matrix-M® adjuvant," said John C. Jacobs, President and Chief Executive Officer, Novavax. "We're pleased to deepen our partnership with leading vaccine innovator, Sanofi, and to share our technology in support of
The amendment broadens the partnership between Novavax and Sanofi and adds to the terms of the original agreement that specifies that Novavax is eligible to receive up to
About Matrix-M® Adjuvant
Matrix-M is Novavax's proprietary adjuvant that can be added to a vaccine to stimulate a stronger immune response and is currently used in globally approved vaccines. It is clinically proven to induce potent, durable and broad immune responses with an acceptable safety and tolerability profile.1 The Company's recombinant, protein-based nanoparticles are combined with its Matrix-M adjuvant, constituting the basis of Novavax's expanding pipeline.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit novavax.com and LinkedIn for more information.
Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, the efficacy, safety and intended utilization of Novavax's COVID-19 vaccine, the possible receipt of potential milestone payments or tiered royalties from vaccine sales, the immunogenic response of its vaccine technology against variant strains and the scope, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges or delays related to the requested postmarketing commitment; antigenic drift or shift in the SARS-CoV-2 spike protein, challenges satisfying, alone or together with partners, various safety, efficacy and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in obtaining regulatory authorization for a JN.1 protein-based COVID-19 vaccine or for future COVID-19 variant strain changes; challenges or delays in clinical trials; manufacturing, distribution or export delays or challenges; Novavax's exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the information identified in the "Risk Factors" section in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
(844) 264-8571
media@novavax.com
References
1. Stertman L. et al.; The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century. Hum Vaccin Immunother. 2023 Dec 31;19(1):2189885. doi: 10.1080/21645515.2023.2189885.
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-announces-progress-on-sanofi-agreement-302570921.html
SOURCE Novavax, Inc.
FAQ
What is the new agreement between Novavax and Sanofi for Matrix-M adjuvant?
How much can Novavax (NVAX) earn from the Sanofi Matrix-M agreement?
What is the role of BARDA in the Novavax-Sanofi collaboration?
What happens when Sanofi reaches Phase 3 development with the vaccine candidate?
What products is Sanofi developing with Novavax's Matrix-M?
